Altus Wealth Group’s Novo Nordisk NVO Stock Holding History

Altus Wealth Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-74	Closed	-$3K	–	580
2020 Q4	$3K	Buy	+74	New	+$2.56K	﹤0.01%	721

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Altus Wealth Group's NVO Position: Q1 2021 in Review

Altus Wealth Group sold out of Novo Nordisk (NVO) in Q1 2021, closing a stake of 74 shares — an estimated $3K sold.

Altus Wealth Group first reported a position in NVO in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 707 funds tracked by Wall St. Rank hold NVO as of Q1 2021.

Altus Wealth Group reported no remaining Novo Nordisk position as of Q1 2021 after selling out during the quarter.
Altus Wealth Group sold 74 Novo Nordisk shares in Q1 2021, an estimated $3K.
Altus Wealth Group first reported a position in Novo Nordisk in Q4 2020 and held it in 1 quarter.
Altus Wealth Group's Novo Nordisk position peaked at $3K in Q4 2020.
707 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2021.

Based on Altus Wealth Group's 13F filing for Q1 2021, filed 14 May 2021.